CD19 and B-cell chronic lymphocytic leukemia: In a pilot/phase I study, CTL019, an anti-CD19 CAR T-cell, was evaluated to determine its safety, efficacy, and cellular kinetics in chemotherapy-resistant or refractory CD19+ CLL.34